Progentec

Progentec Diagnostics, founded in 2014 by Mohan Purushothaman, is a digital health and diagnostics company concentrating on the management of autoimmune diseases. The company is headquartered in Oklahoma City and operates at the intersection of laboratory diagnostics and digital therapeutics to address chronic conditions like systemic lupus erythematosus (SLE) and multiple sclerosis. Mohan Purushothaman, who serves as President and CEO, brings extensive experience from the pharmaceutical industry, including leadership roles in pricing and market access at Roche and Alliance Life Sciences, complemented by a Ph.D. from Johns Hopkins University.

Progentec's business model centers on developing and commercializing a suite of proprietary biomarker blood tests and digital health tools that enable proactive care. These offerings are designed to serve rheumatologists, neurologists, and other healthcare providers by providing predictive insights for better care decisions. Revenue is generated through its advanced testing services, which are made available to clinicians via partnerships, most notably a collaboration with Mayo Clinic Laboratories that launched in 2023. This strategic alliance expanded the accessibility of Progentec's tests across the U.S. and other selected global markets. The company's funding journey includes multiple rounds, culminating in a total of $8.75M, with a significant $5M Series A round in 2020 and a grant in June 2024.

The company’s core products are the aiSLE® DX tests for lupus management, which became available through Mayo Clinic Laboratories in April 2024. The aiSLE® DX Flare Risk Index uses an 11-biomarker panel to forecast the likelihood of a lupus flare within the subsequent 12 weeks. The aiSLE® DX Disease Activity Index employs a 10-biomarker panel to help clinicians assess current disease activity, which can inform treatment strategies and the frequency of patient monitoring. Beyond laboratory tests, Progentec has strengthened its digital health capabilities through the 2018 acquisition of LupusCorner, a patient engagement platform. This integration added a suite of tools, including a community forum and a research app, enhancing the company's ability to collect patient-reported outcomes and develop digital biomarkers. Progentec is also actively developing new laboratory and digital biomarkers for multiple sclerosis.

Keywords: autoimmune disease diagnostics, lupus management, multiple sclerosis testing, digital health, biomarker blood tests, proactive care, rheumatology diagnostics, flare prediction, disease activity index, Mayo Clinic Laboratories partner, proteomics, digital therapeutics, aiSLE DX, LupusCorner, Mohan Purushothaman, patient monitoring, chronic disease management, CLIA laboratory, remote monitoring, personalized medicine